Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study

C. F. Pollera, A. Ceribelli, M. Crecco, F. Calabresi

Research output: Contribution to journalArticle

Abstract

Background: Gemcitabine (2'2-difluorodeoxycytidine; GEM) is a novel deoxycytidine analogue with promising antitumor activity, currently under phase II investigation at doses ≥800 mg/m2/week. Patients and methods: The present report summarizes the results obtained in a cohort of 15 patients with metastatic bladder cancer included in a larger phase I study, receiving GEM at therapeutically active doses (≥875 mg/m2/week x 3 every 28 days). Except for 1 chemotherapy-naive patient, all had received prior chemotherapy with the M-VAC regimen. Results: All but 1 patient were given GEM doses exceeding 1,000 mg/m2 (1 case at 875, 3 at 1,095 and 11 at 1,370 mg/m2) for a total of 50 delivered courses. One complete and 2 partial remissions were seen among 14 previously treated patients. Furthermore, 1 additional partial remission was observed in the single case with no prior chemotherapy, for an overall response rate of 27% (90% C.I. 4.3%-49.1%). All responders had visceral sites of disease. Dose-limiting hematologic toxicity was found at 1,370 mg/m2/wk as underscored by the higher number of toxic treatment delays requiring subsequent dose attenuation in 6 of 11 patients. Toxicity was mild and easily managed. It included (patients with WHO grade 2-3): leukopenia (53%), thrombocytopenia (20%), anemia (53%), AST/ALT rise (27%) and (grade 2 only) fever (60%) and emesis (40%). Conclusions: The favourable tolerability and evidence of antitumor activity of GEM in patients with bladder cancer and prior M-VAC at doses ≥875 mg/m2/wk are encouraging and deserve confirmation in larger phase II studies.

Original languageEnglish
Pages (from-to)182-184
Number of pages3
JournalAnnals of Oncology
Volume5
Issue number2
Publication statusPublished - 1994

Fingerprint

gemcitabine
Bladder Cancer
Air cushion vehicles
Urinary Bladder Neoplasms
Chemotherapy
Dose
Toxicity
Drug Therapy
Partial
Attenuation
Deoxycytidine
Cancer
Poisons
Leukopenia
Limiting
Thrombocytopenia
Analogue
Vomiting
Anemia

Keywords

  • bladder cancer
  • gemcitabine
  • phase I study

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Hematology

Cite this

Pollera, C. F., Ceribelli, A., Crecco, M., & Calabresi, F. (1994). Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Annals of Oncology, 5(2), 182-184.

Weekly gemcitabine in advanced bladder cancer : A preliminary report from a phase I study. / Pollera, C. F.; Ceribelli, A.; Crecco, M.; Calabresi, F.

In: Annals of Oncology, Vol. 5, No. 2, 1994, p. 182-184.

Research output: Contribution to journalArticle

Pollera, CF, Ceribelli, A, Crecco, M & Calabresi, F 1994, 'Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study', Annals of Oncology, vol. 5, no. 2, pp. 182-184.
Pollera, C. F. ; Ceribelli, A. ; Crecco, M. ; Calabresi, F. / Weekly gemcitabine in advanced bladder cancer : A preliminary report from a phase I study. In: Annals of Oncology. 1994 ; Vol. 5, No. 2. pp. 182-184.
@article{aa87bc467bad49f78650558c58ac8225,
title = "Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study",
abstract = "Background: Gemcitabine (2'2-difluorodeoxycytidine; GEM) is a novel deoxycytidine analogue with promising antitumor activity, currently under phase II investigation at doses ≥800 mg/m2/week. Patients and methods: The present report summarizes the results obtained in a cohort of 15 patients with metastatic bladder cancer included in a larger phase I study, receiving GEM at therapeutically active doses (≥875 mg/m2/week x 3 every 28 days). Except for 1 chemotherapy-naive patient, all had received prior chemotherapy with the M-VAC regimen. Results: All but 1 patient were given GEM doses exceeding 1,000 mg/m2 (1 case at 875, 3 at 1,095 and 11 at 1,370 mg/m2) for a total of 50 delivered courses. One complete and 2 partial remissions were seen among 14 previously treated patients. Furthermore, 1 additional partial remission was observed in the single case with no prior chemotherapy, for an overall response rate of 27{\%} (90{\%} C.I. 4.3{\%}-49.1{\%}). All responders had visceral sites of disease. Dose-limiting hematologic toxicity was found at 1,370 mg/m2/wk as underscored by the higher number of toxic treatment delays requiring subsequent dose attenuation in 6 of 11 patients. Toxicity was mild and easily managed. It included (patients with WHO grade 2-3): leukopenia (53{\%}), thrombocytopenia (20{\%}), anemia (53{\%}), AST/ALT rise (27{\%}) and (grade 2 only) fever (60{\%}) and emesis (40{\%}). Conclusions: The favourable tolerability and evidence of antitumor activity of GEM in patients with bladder cancer and prior M-VAC at doses ≥875 mg/m2/wk are encouraging and deserve confirmation in larger phase II studies.",
keywords = "bladder cancer, gemcitabine, phase I study",
author = "Pollera, {C. F.} and A. Ceribelli and M. Crecco and F. Calabresi",
year = "1994",
language = "English",
volume = "5",
pages = "182--184",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Weekly gemcitabine in advanced bladder cancer

T2 - A preliminary report from a phase I study

AU - Pollera, C. F.

AU - Ceribelli, A.

AU - Crecco, M.

AU - Calabresi, F.

PY - 1994

Y1 - 1994

N2 - Background: Gemcitabine (2'2-difluorodeoxycytidine; GEM) is a novel deoxycytidine analogue with promising antitumor activity, currently under phase II investigation at doses ≥800 mg/m2/week. Patients and methods: The present report summarizes the results obtained in a cohort of 15 patients with metastatic bladder cancer included in a larger phase I study, receiving GEM at therapeutically active doses (≥875 mg/m2/week x 3 every 28 days). Except for 1 chemotherapy-naive patient, all had received prior chemotherapy with the M-VAC regimen. Results: All but 1 patient were given GEM doses exceeding 1,000 mg/m2 (1 case at 875, 3 at 1,095 and 11 at 1,370 mg/m2) for a total of 50 delivered courses. One complete and 2 partial remissions were seen among 14 previously treated patients. Furthermore, 1 additional partial remission was observed in the single case with no prior chemotherapy, for an overall response rate of 27% (90% C.I. 4.3%-49.1%). All responders had visceral sites of disease. Dose-limiting hematologic toxicity was found at 1,370 mg/m2/wk as underscored by the higher number of toxic treatment delays requiring subsequent dose attenuation in 6 of 11 patients. Toxicity was mild and easily managed. It included (patients with WHO grade 2-3): leukopenia (53%), thrombocytopenia (20%), anemia (53%), AST/ALT rise (27%) and (grade 2 only) fever (60%) and emesis (40%). Conclusions: The favourable tolerability and evidence of antitumor activity of GEM in patients with bladder cancer and prior M-VAC at doses ≥875 mg/m2/wk are encouraging and deserve confirmation in larger phase II studies.

AB - Background: Gemcitabine (2'2-difluorodeoxycytidine; GEM) is a novel deoxycytidine analogue with promising antitumor activity, currently under phase II investigation at doses ≥800 mg/m2/week. Patients and methods: The present report summarizes the results obtained in a cohort of 15 patients with metastatic bladder cancer included in a larger phase I study, receiving GEM at therapeutically active doses (≥875 mg/m2/week x 3 every 28 days). Except for 1 chemotherapy-naive patient, all had received prior chemotherapy with the M-VAC regimen. Results: All but 1 patient were given GEM doses exceeding 1,000 mg/m2 (1 case at 875, 3 at 1,095 and 11 at 1,370 mg/m2) for a total of 50 delivered courses. One complete and 2 partial remissions were seen among 14 previously treated patients. Furthermore, 1 additional partial remission was observed in the single case with no prior chemotherapy, for an overall response rate of 27% (90% C.I. 4.3%-49.1%). All responders had visceral sites of disease. Dose-limiting hematologic toxicity was found at 1,370 mg/m2/wk as underscored by the higher number of toxic treatment delays requiring subsequent dose attenuation in 6 of 11 patients. Toxicity was mild and easily managed. It included (patients with WHO grade 2-3): leukopenia (53%), thrombocytopenia (20%), anemia (53%), AST/ALT rise (27%) and (grade 2 only) fever (60%) and emesis (40%). Conclusions: The favourable tolerability and evidence of antitumor activity of GEM in patients with bladder cancer and prior M-VAC at doses ≥875 mg/m2/wk are encouraging and deserve confirmation in larger phase II studies.

KW - bladder cancer

KW - gemcitabine

KW - phase I study

UR - http://www.scopus.com/inward/record.url?scp=0028039840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028039840&partnerID=8YFLogxK

M3 - Article

C2 - 8186164

AN - SCOPUS:0028039840

VL - 5

SP - 182

EP - 184

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -